Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05136807
Other study ID # 2016-0172
Secondary ID NCI-2021-1111820
Status Recruiting
Phase
First received
Last updated
Start date June 7, 2016
Est. completion date February 2, 2027

Study information

Verified date May 2024
Source M.D. Anderson Cancer Center
Contact Melody Becnel, MD
Phone 832-206-9804
Email mrbecnel@mdanderson.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.


Description:

PRIMARY OBJECTIVE: I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM already participating in clinical trials at MD Anderson Cancer Center. SECONDARY OBJECTIVE: I. Identify the most common symptoms/patients concerns to evaluate future interventions for treatment/prevention in this population. OUTLINE: Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date February 2, 2027
Est. primary completion date February 2, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with either monoclonal gammopathy of unknown significance age >= 18 years old. - Both criteria must be met: - Serum monoclonal protein < 3 g/dL or urinary monoclonal protein < 500 mg per 24 hours and clonal bone marrow plasma cells < 10% - Absence of myeloma defining events or amyloidosis - OR Patients with smoldering multiple myeloma age >= 18 years old. - Both criteria must be met: - Serum monoclonal protein >= 3 g/dL or urinary monoclonal protein >= 500 mg per 24 hours and/or clonal bone marrow plasma cells 10-60% - Absence of myeloma defining events or amyloidosis - Patients must be enrolled in clinical trials for SMM or MGUS at MD Anderson Cancer Center, including protocols PA15-0575 (NCT02726750) (Prospective observational study of clinical and genomic predictors of progression to myeloma in asymptomatic monoclonal gammopathies); 2015-0148 (Phase II single arm trial of Isatuximab in patients with intermediate and high risk smoldering multiple myeloma); and 2015-0371 (NCT02603887) (Pilot single arm, single center, open label trial of Pembrolizumab in patients with intermediate and high risk smoldering multiple myeloma) and any future clinical trials for MGUS and/or SMM that open at MD Anderson Cancer Center. - Only patients who are English or Spanish speaking are eligible. Exclusion Criteria: - Evidence of myeloma defining events or biomarkers of malignancy due to underlying plasma cell proliferative disorder meeting at least one of the following - Hypercalcemia: serum calcium > 0.25 mmol/L (> 1 mg/dL) higher than the upper limit of normal or > 2.75 mmol/L (> 11 mg/dL) - Renal Insufficiency: creatinine clearance < 40 ml/min or serum creatinine > 2 mg/dL - Anemia: hemoglobin value < 10 g/dL or 2 g/dL < normal reference - Bone lesions: one or more osteolytic lesions on skeletal radiography, computerized tomography (CT) or 2-deoxy-2[F-18] fluoro-D-glucose positron emission tomography CT (PET-CT). - Clonal bone marrow plasma cell percentage >= 60% - Involved: uninvolved serum free light chain ratio >= 100 measured by Freelite assay (The Binding Site Group, Birmingham, United Kingdom [UK]) - >1 focal lesions on magnetic resonance imaging (MRI) studies, if the patient has an MRI done per eligibility criteria (each focal lesion must be 5 mm or more in size) - Plasma cell leukemia. - Presence of cognitive impairment or delirium as determined by the primary clinician.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Quality-of-Life Assessment
Complete questionnaires
Questionnaire Administration
Complete questionnaires

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of life questionnaires Patients complete quality of life questionnaires over 10-15 minutes at baseline.
Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time
Up to 3 years
Primary Quality of life questionnaires Patients complete quality of life questionnaires every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years.
Score scale ranges from (1-4) 1 - Not at all and 4 - Almost all the time
Up to 3 years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Not yet recruiting NCT04702932 - Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Active, not recruiting NCT03327597 - Iceland Screens, Treats or Prevents Multiple Myeloma N/A
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Phase 1
Completed NCT01955395 - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma N/A
Completed NCT01219010 - A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Phase 1
Completed NCT01237054 - Imaging in MGUS, SMM and MM Phase 2
Active, not recruiting NCT03855878 - Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery
Recruiting NCT05640843 - A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Completed NCT00099047 - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Phase 2
Completed NCT00919139 - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. N/A
Not yet recruiting NCT05114109 - Isatuximab in Type I Cryoglobulinemia Phase 2
Recruiting NCT04114084 - Sleep Apnea in Patients With MGUS and MM
Recruiting NCT06383143 - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Withdrawn NCT01571726 - Imaging Studies and the Development of Multiple Myeloma Phase 2
Recruiting NCT01408225 - Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Active, not recruiting NCT04920084 - A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Recruiting NCT06046287 - Daratumumab for Polyneuropathy Associated With MGUS Phase 2
Recruiting NCT03119883 - Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma N/A

External Links